Day: October 26, 2022

On October 15, 2007, Wang, Jian; Djukic, Brandon; Cao, Jingyi; Alberola, Antonio; Razavi, Fereidoon S.; Pilkington, Melanie published an article.HPLC of Formula: 75449-26-2 The title of the article was A novel bis tridentate bipyridine carboxamide ligand and its complexation to copper(II): synthesis, structure, and magnetism. And the article contained the following:

A new bis tridentate ligand 2,2′-bipyridine-3,3′-[2-pyridinecarboxamide] H2L1 which can bind transition metal ions was synthesized via the condensation of 3,3′-diamino-2,2′-bipyridine together with 2-pyridine carbonyl chloride. Two Cu(II) coordination compounds were prepared and characterized: [Cu2(L1)(hfac)2].3MeCN.H2O (1) and [Cu2(L1)Cl2].MeCN (2). The single-crystal x-ray structures reveal that complex 1 crystallizes in the triclinic space group P1̅, with a 12.7185(6), b 17.3792(9), c 19.4696(8) Å, α 110.827(2), β 99.890(3), γ 97.966(3)°, Z = 4, R = 0.0321 and Rw = 0.0826. Complex 2 crystallizes in the monoclinic space group P21/n with a 12.8622(12), b 9.6100(10), c 19.897(2) Å, β 102.027(3)°, Z = 4, R = 0.0409 and Rw = 0.1005. In both complexes the ligand is in the dianionic form and coordinates the divalent CuII ions via one amido and two pyridine N donor atoms. In 1, the coordination geometry around both CuII ions is best described as distorted trigonal bipyramidal where the remaining two coordination sites are satisfied by hexafluoroacetylacetonate counterions. In 2 both CuII ions adopt a (4 + 1) distorted square pyramidal geometry. One Cu forms a longer apical bond to an adjacent carbonyl O atom, whereas the second Cu is chelated to a neighboring Cu-Cl chloride ion to afford a μ-Cl-bridged dimerized [Cu2(L1)Cl2]2 complex. The magnetic susceptibility data for 1 (2 -270 K), reveal the occurrence of weak antiferromagnetic interactions between the CuII ions. In contrast, variable-temperature magnetic susceptibility measurements for 2 reveal more complex magnetic properties, with the presence of a weak antiferromagnetic exchange (J = -10.1 K) between the Cu ions in each dinuclear Cu complex and a stronger ferromagnetic exchange interaction (J = 32.9 K) between the CuII ions of the Cu(μ-Cl)2Cu dimeric bridging units. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).HPLC of Formula: 75449-26-2

The Article related to copper bipyridinepyridinecarboxamide preparation structure magnetic exchange, crystal structure copper bipyridinepyridinecarboxamide fluoroacac chloro dinuclear, exchange ferromagnetic antiferromagnetic copper bipyridinepyridinecarboxamide and other aspects.HPLC of Formula: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 21, 2005, Kelly, Michael G.; Janagani, Satyanarayana; Wu, Guoxian; Kincaid, John; Lonergan, David; Fang, Yunfeng; Wei, Zhi-Liang published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of bicycloheteroarylamines like 2,6-naphthyridinamines and pyrido[3,4-d]pyrimidinamine as ion channel ligands and uses thereof. And the patent contained the following:

Amine compounds (shown as I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; and stereoisomers and tautomers thereof; variables defined below; e.g. 7-(3-chloropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine (shown as II)) that are VR1 (VR = vanilloid receptor) antagonists are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of nonlimiting example, pain, inflammation, traumatic injury, and others. Compounds I are considered to be particularly beneficial as VR1 antagonists as certain compounds exhibit improved aqueous solubility and metabolic stability. For I: A and B = CH2, CR2’R2′, CO, CS and NR2′; Y = CH2, CR2’R2′ and NR2′; W and Z = CR4 and N, provided that W and Z both can not be N; R1 = (un)substituted aliphatic, alkyl, heteroalkyl, acyl, aryl, heteroaryl, aralkyl, heteroalkyl; each of R2 and R2′ = H, or (un)substituted C1-C6 alkyl, C1-C6 cycloalkyl, aryl and aralkyl; R3 = (un)substituted C1-C6 alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, bicycloalkyl, bicycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, and bicycloheteroaryl ring. R4 = H, or (un)substituted alkyl, (un)substituted acyl, (un)substituted acylamino, (un)substituted alkylamino, (un)substituted alkylthio, (un)substituted alkoxy, (un)substituted alkoxycarbonyl, (un)substituted alkylarylamino, (un)substituted arylalkyloxy, amino, (un)substituted aryl, arylalkyl, (un)substituted sulfoxide, (un)substituted sulfone, (un)substituted mercapto, (un)substituted aminosulfonyl, (un)substituted arylsulfonyl, sulfuric acid, sulfuric acid ester, (un)substituted dihydroxyphosphoryl, (un)substituted aminodihydroxyphosphoryl, azido, carboxy, (un)substituted carbamoyl, carboxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl, (un)substituted dialkylamino, halo, heteroaryloxy, (un)substituted heteroaryl, (un)substituted heteroalkyl, hydroxy, nitro, and thio. Although the methods of preparation are not claimed, 62 example preparations are included. For example, II was prepared in 5 steps (90, 38, 91, 87, 26 % yields) starting from 1-benzyl-3-(ethoxycarbonyl)-4-piperidone hydrochloride, formamidine acetate and NaOMe/MeOH and involving intermediates 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one, 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 7-benzyl-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine, and N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine. VR1 antagonist activity for 62 examples of I, capsaicin-induced VR1 current inhibition activity for 16 examples of I, reversal of thermal hyperalgesia in rats by II, pharmacokinetic profiles for 5 examples of I and plasma protein binding ability by II are reported. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to naphthyridinamine pyridopyrimidinamine preparation vanilloid receptor antagonist, ion channel ligand naphthyridinamine pyridopyrimidinamine preparation, pain inflammation traumatic injury drug naphthyridinamine pyridopyrimidinamine preparation and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 29, 1992, Alo, Babajide I.; Familoni, Oluwole B.; Marsais, Francis; Queguiner, Guy published an article.Safety of Pyridine-3-sulfonic acid The title of the article was Directed metalation of pyridinesulfonamides. Synthesis of pyridine-fused isothiazoles and 1,2-oxathioles. And the article contained the following:

4-Lithio-N-tert-butylpyridine-3-sulfonamide reacted with Ph2CO or CO2 to give the corresponding intermediates, which on appropriate treatment gave the addition product I (from Ph2CO reaction product) or isothiazolo[5,4-c]pyridin-3-one 1,1-dioxides II (R = H, Me3C) (from CO2 reaction product). Metalation of 2- and 4-[N,N-(dialkylamino)sulfonyl]pyridines with LiN(CHMe2)2 gave anions which reacted with Ph2CO to give carbinols, which cyclized thermally to 1,2-oxathiolo[3,4-b]- III and -[4,3-c]pyridine dioxide IV, resp. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Safety of Pyridine-3-sulfonic acid

The Article related to sultone pyridine fused, sultam pyridine fused, pyridinesulfonamide directed lithiation, isothiazolopyridinone dioxide, oxathiolopyridine, aminosulfonylpyridine lithiated reaction benzophenone, intramol cyclocondensation sulfonylpyridylmethanol and other aspects.Safety of Pyridine-3-sulfonic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 21, 2006, van Herrikhuyzen, Jeroen; Jonkheijm, Pascal; Schenning, Albertus P. H. J.; Meijer, E. W. published an article.Quality Control of [2,2′-Bipyridine]-3,3′-diamine The title of the article was The influence of hydrogen bonding and π-π stacking interactions on the self-assembly properties of C3-symmetrical oligo(p-phenylenevinylene) discs. And the article contained the following:

Three nonracemic C3-sym. oligophenylenevinylenes (OPV) are prepared and characterized; the UV/visible and IR spectra of the products in solution are determined and used to characterize the structures formed by self-assembly of the OPV. OPVs with triaminobenzene and benzenetricarboxamide cores show two-step transitions from helical stacks to molecularly dissolved species; the orientation of the amide relative to the core determines the stabilities and helicities of fibers in solution and the lengths of fibrils formed at surfaces. An OPV with a tris(2,2′-bipyridin-3-yl)benzenetricarboxamide core forms aggregates that show little chiral ordering but which remain present over a large temperature range; at surfaces, completely disordered structures exist as a result of competing types of π-π stacking interactions that differ in strength and orientation. The design of functional self-assembled architectures based on hydrogen bonding and π-π stacking interactions requires careful balancing of the topologies, directionalities and strengths of secondary interactions. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Quality Control of [2,2′-Bipyridine]-3,3′-diamine

The Article related to oligophenylenevinylene nonracemic preparation uv visible spectra self assembly, aggregation pi stacking hydrogen bonding interaction nonracemic oligophenylenevinylene, hydrogen bonding pi interaction self assembly sym oligophenylenevinylene disk and other aspects.Quality Control of [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 28, 2021, Cuthbertson, Alan; Boehnke, Niels published a patent.HPLC of Formula: 282734-37-6 The title of the patent was Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer. And the patent contained the following:

The invention is related to the preparation of compounds I [n = 1-3; R1-4 = OH or Q; Q = a tissue-targeting moiety selected from the group consisting of poly- and oligopeptides, proteins, DNA and RNA fragments, aptamers polyclonal or monoclonal antibodies, and a mixture of proteins or fragments or constructs of protein] their stereoisomers, hydrates, solvates and salts, and targeted radiopharmaceuticals, pharmaceutical compositions and combinations comprising them and their use for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients. The experimental process involved the reaction of (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-bromopyridin-2-yl)propanoic acid(cas: 282734-37-6).HPLC of Formula: 282734-37-6

The Article related to peptide chelator conjugate preparation antitumor prostate cancer, preparation peptide chelator thorium 227 her2 fap psma conjugate, prostate specific membrane antigen carboxy hopo thorium 227 conjugate, targeted radiopharmaceutical prostate cancer and other aspects.HPLC of Formula: 282734-37-6

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 5, 2014, Walsh, Shawn P.; Cato, Brian; Frie, Jessica L.; Kim, Dooseop; Pasternak, Alexander; Shi, Zhi-Cai published a patent.Recommanded Product: 868551-99-9 The title of the patent was Preparation of piperidine derivatives as inhibitors of the renal outer medullary potassium channel for treating cardiovascular diseases and edematous conditions. And the patent contained the following:

The present invention provides compounds of Formula I (wherein n = 0-1; the N-containing ring system is (un)substituted piperidinyl, etc.; R1 is -H, -OC1-3alkyl or -OH; R2 is -H or C1-3alkyl; R3 is -H, -F, -C1-3 alkyl or phenyl; or when n is 0, R2 and R3 are joined together to form a 4-6 member ring with the nitrogen and carbon to which each is attached; R4 and R5 are each independently -H or -C1-3-alkyl, or R4 and R5 are joined together with the carbon to which they are attached to form C3-6 cycloalkyl; Z1 is (un)substituted Ph, (un)substituted benzofuranyl, or (un)substituted benzopyranyl, and Z2 is a substituted N-containing heterocyclyl, (un)substituted Ph, etc.), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting intermediates 1-oxo-N-(piperidin-4-yl)-1,3-dihydroisobenzofuran-5-carboxamide hydrochloride and (4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetaldehyde. In the ROMK channel functional thallium flux assay, II had an IC50 of 0.01 μM. The experimental process involved the reaction of Methyl 5-amino-4-methylpicolinate(cas: 868551-99-9).Recommanded Product: 868551-99-9

The Article related to preparation piperidine derivative inhibitor renal medullary potassium channel, cardiovascular disease piperidine derivative inhibitor renal medullary potassium channel, edema treatment piperidine derivative inhibitor renal medullary potassium channel and other aspects.Recommanded Product: 868551-99-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 21, 2022, Rai, Roopa; Booth, Robert published a patent.COA of Formula: C9H14N2 The title of the patent was Preparation of 1H-pyrrolo[2,3-b]pyridine derivatives as PGDH inhibitors and inhalation formulations thereof. And the patent contained the following:

Disclosed are compounds that inhibit 15-hydroxy-prostaglandin dehydrogenase (PGDH) thus modulating prostaglandin levels which may be useful for the treatment of respiratory disorders such as COPD and idiopathic pulmonary fibrosis. Compounds of formula I [wherein R1 = (un)substituted C6-10aryl and 5- to 10-membered heteroaryl; R2 = H and R3 = CF3; R2 and R3 together = O; each R4 and R5 independently = halo, OH and derivatives, NH2 and derivatives, etc.; m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n = 1, 2, 3, or 4; p = 0, 1, 2, or 3] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compound II was prepared from a multistep procedure (preparation given). Exemplified I were evaluated for PGDH inhibitory activity from which II demonstrated an IC50 of < 0.1μM. In some embodiments, the compounds disclosed herein are formulated for delivery via inhalation. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).COA of Formula: C9H14N2

The Article related to pyrrolopyridine carboxamide derivative preparation inhalant formulation, hydroxyprostaglandin dehydrogenase inhibitor preparation pulmonary fibrosis copd, benzimidazole azabenzimidazole indole benzoxazine carboxamide preparation prostaglandin inhibitor and other aspects.COA of Formula: C9H14N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 15, 2014, Ghaffari, Behnaz; Preshlock, Sean M.; Plattner, Donald L.; Staples, Richard J.; Maligres, Peter E.; Krska, Shane W.; Maleczka, Robert E.; Smith, Milton R. published an article.Electric Literature of 1349171-28-3 The title of the article was Silyl Phosphorus and Nitrogen Donor Chelates for Homogeneous Ortho Borylation Catalysis. And the article contained the following:

Ir catalysts supported by ortho-(diisopropylsilyl)(di-p-tolylphosphino)benzene bidentate ligand that contains P- or N-donors, effects ortho-borylations for a range of substituted aromatics E.g., reaction of C6H5CO2Me with bis(pinacolato)diboron (B2pin2) in the presence of 1.25 mol% [Ir(OMe)(cod)]2/ 2.5 mol% (p-tol)2PC6H4-2-(SiHiPr2) in THF at 80° to give 72% yield of Me 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate. The substrate scope is broad, and the modular ligand synthesis allows for flexible catalyst design. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Electric Literature of 1349171-28-3

The Article related to ortho silylphosphinylbenzene tethered iridium cyclooctadiene preparation catalyst orthoborylation, crystal structure ortho silylphosphinylbenzene tethered iridium cyclooctadiene, mol structure ortho silylphosphinylbenzene tethered iridium cyclooctadiene and other aspects.Electric Literature of 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 31, 1979, Sadikov, A. S.; Otroshchenko, O. S.; Yunusov, T. K. published an article.Category: pyridine-derivatives The title of the article was Sulfur-containing derivatives of anabasine and its analogs. And the article contained the following:

Treatment of anabasine, isoanabasine and 2,3′-dipiperidyl with SOCl2, SCl2, elemental S, concentrated H2SO4, and sulfoacids of N heterocyclic bases gave a series of biol. active S-containing derivatives, e.g. I and II, of anabasine and its analogs. Dependences between the structure of substrates and their chem. reactivity were discussed. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Category: pyridine-derivatives

The Article related to anabasine reaction sulfur compound, isoanabasine reaction sulfur, dipiperidyl reaction sulfur, sulfur reaction anabasine, thionyl chloride reaction anabasine, sulfur chloride reaction anabasine, sulfuric acid reaction anabasine, sulfo acid reaction anabasine and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 10, 2021, Karges, Johannes; Kalaj, Mark; Gembicky, Milan; Cohen, Seth M. published an article.Reference of [2,2′-Bipyridine]-3,3′-diamine The title of the article was ReI tricarbonyl complexes as coordinate covalent inhibitors for the SARS-CoV-2 main cysteine protease. And the article contained the following:

Since its outbreak, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has impacted the quality of life and cost hundreds-of-thousands of lives worldwide. Based on its global spread and mortality, there is an urgent need for novel treatments which can combat this disease. To date, the 3-chymotrypsin-like protease (3CLpro), which is also known as the main protease, is considered among the most important pharmacol. targets. The vast majority of investigated 3CLpro inhibitors are organic, non-covalent binders. Herein, the use of inorganic, coordinate covalent binders is proposed that can attenuate the activity of the protease. ReI tricarbonyl complexes were identified that demonstrate coordinate covalent enzymic inhibition of 3CLpro. Preliminary studies indicate the selective inhibition of 3CLpro over several human proteases. This study presents the first example of metal complexes as inhibitors for the 3CLpro cysteine protease. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Reference of [2,2′-Bipyridine]-3,3′-diamine

The Article related to rhenium tricarbonyl complex coordinate inhibitor main protease sars cov2, synthesis crystal structure rhenium tricarbonyl complex protease inhibitor 3clpro, sars-cov-2, antiviral agents, bioinorganic chemistry, medicinal inorganic chemistry, protease inhibitor and other aspects.Reference of [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem